Claims for Patent: 9,855,246

Summary for Patent: 9,855,246

Title:	Stable preservative-free mydriatic and anti-inflammatory solutions for injection
Abstract:	The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.
Inventor(s):	Demopulos; Gregory A. (Mercer Island, WA), Shen; Hui-rong (Bothell, WA), Tedford; Clark E. (Poulsbo, WA)
Assignee:	Omeros Corporation (Seattle, WA)
Application Number:	15/278,514
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,855,246
Patent Claims:	1. A liquid intraocular ophthalmic pharmaceutical solution dosage form consisting essentially of phenylephrine, ketorolac, and a buffer system, in solution in a pH-adjusted aqueous carrier as a solvent, that is free of preservatives, antioxidants and solubilizing agents, and a nitrogen gas overlay in a single-use container, wherein the phenylephrine is included at a concentration of 45 mM to 76 mM and the ketorolac is included at a concentration of about 8.5 mM to 14 mM, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least six months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C. 2. The dosage form of claim 1, wherein the dosage form is free of visible precipitation and crystallization. 3. The dosage form of claim 2, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least 24 months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C. 4. The dosage form of claim 3, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least 30 months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C. 5. The dosage form of claim 1, wherein the buffer system comprises an about 20 mM sodium citrate buffer system. 6. The dosage form of claim 1, wherein the phenylephrine is included at a concentration of about 60.75 mM and the ketorolac is included at a concentration of about 11.25 mM. 7. The dosage form of claim 1, wherein the solution has a pH of from 5.8 to 6.8. 8. The dosage form of claim 7, wherein the pH of the solution is adjusted by adding sodium hydroxide and/or hydrochloric acid as may be required. 9. The dosage form of claim 1, wherein: the dosage form is free of visible precipitation and crystallization; the buffer system comprises an about 20 mM sodium citrate buffer system; the phenylephrine is included at a concentration of about 60.75 mM and the ketorolac is included at a concentration of about 11.25 mM; the solution has a pH of from 5.8 to 6.8 that has been adjusted with sodium hydroxide and/or hydrochloric acid as may be required. 10. A liquid intraocular ophthalmic pharmaceutical solution consisting essentially of phenylephrine, ketorolac, and a sodium citrate buffer system, in solution in an aqueous carrier as a solvent that is adjusted to a pH of from 5.8 to 6.8, that is free of preservatives, antioxidants and solubilizing agents, wherein the phenylephrine is included at a concentration of about 60.75 mM and the ketorolac is included at a concentration of about 11.25 mM, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least six months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C. 11. The solution of claim 10, wherein the solution is free of visible precipitation and crystallization. 12. The solution of claim 10, wherein the solution is stable for a period of at least 30 months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C. 13. A liquid intraocular ophthalmic pharmaceutical solution comprising phenylephrine, ketorolac, and a sodium citrate buffer system, in solution in an aqueous carrier as a solvent that is adjusted to a pH of from 5.8 to 6.8, that is free of preservatives, antioxidants and solubilizing agents, wherein the phenylephrine is included at a concentration of about 60.75 mM and the ketorolac is included at a concentration of about 11.25 mM, wherein the intraocular ophthalmic pharmaceutical solution is stable for a period of at least six months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C. 14. The solution of claim 13, wherein the solution is free of visible precipitation and crystallization. 15. The solution of claim 13, wherein the solution is stable for a period of at least 30 months when stored at a temperature of from 5+/-3.degree. C. to 25+/-2.degree. C.